Catalent Pharma Solutions
14 Schoolhouse Road
Somerset, NJ 08873
T : +1-888-SOLUTION (USA)
T : 00800 88 55 6178 (Europe/RoW)
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and reliable global supply.
Catalent has built this expertise with partners of all sizes, from the smallest innovators to the largest of pharmaceutical leaders, advancing thousands of molecules through development towards commercial supply.
Providing both specific, tailored program support and comprehensive, integrated solutions, Catalent reduces its partners’ risks on a variety of programs, including orphan drugs, accelerated and breakthrough treatments, vaccines, next-generation cell and gene therapies, and rare diseases.
Its team of approximately 14,000, at 45+ global sites, manages over 1,100 active development programs and supports more than 180 product launches annually. Every year, Catalent produces more than 72 billion doses of over 7,000 products for more than 1,000 customers, equating to 1 in 20 doses taken by patients globally.
With its expert services including analytical, biologics, preformulation, and formulation, Catalent drives faster, more efficient development of differentiated and patient-preferred products, including:
-Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies, as well as autologous and allogeneic cell therapy development and manufacturing
-GPEx® Boost technology for advanced cell expression, biopharmaceutical development, bioanalytics and biomanufacturing
-Proprietary SMARTag® site-specific bioconjugation technology, affording precision design of next-generation biologic therapies
-OptiForm® Solution Suite for rapid, optimized dose form development
-Bioavailability enhancement including lipid-based systems, spray dry technology, particle-size engineering, and OptiMelt® hot melt extrusion
-Unique delivery technologies: including OptiShell® gelatin-free capsule technology, the Zydis® orally disintegrating tablet platform, OptiGel® DR and other oral controlled release dose design, as well as inhaled and injectable dose forms
-Catalent R P Scherer® Softgel, a global leader in innovative oral and topical softgel technologies. Nearly 90% of NCEs approved by the FDA over the last 25 years have been developed by Catalent
Catalent offers a number of integrated solutions to accelerate clinical and commercial development:
-OneBio® Suite, reduces timelines, risk and complexity for biopharmaceuticals from cell line development through to clinical supply
-OptiForm® Total Supply accelerates drug candidates from development to clinical phase
-OneXpressTM provides the fastest pathway from clinical development to commercial manufacturing
More products. Better treatments. Reliably suppliedTM
Posted Date: 12/3/2020
This record has been viewed 6070 times.